DK0682017T3 - Substituerede bicycliske heteroaroylguanidiner, fremgangsmåde til deres fremstilling, deres anvendelse som lægemiddel eller - Google Patents

Substituerede bicycliske heteroaroylguanidiner, fremgangsmåde til deres fremstilling, deres anvendelse som lægemiddel eller

Info

Publication number
DK0682017T3
DK0682017T3 DK95106596T DK95106596T DK0682017T3 DK 0682017 T3 DK0682017 T3 DK 0682017T3 DK 95106596 T DK95106596 T DK 95106596T DK 95106596 T DK95106596 T DK 95106596T DK 0682017 T3 DK0682017 T3 DK 0682017T3
Authority
DK
Denmark
Prior art keywords
poly
drug
processes
preparation
ring
Prior art date
Application number
DK95106596T
Other languages
Danish (da)
English (en)
Inventor
Jan-Robert Dr Schwark
Heinz-Werner Dr Kleemann
Hans-Jochen Dr Lang
Andreas Dr Weichert
Wolfgang Dr Scholz
Udo Dr Albus
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Application granted granted Critical
Publication of DK0682017T3 publication Critical patent/DK0682017T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/08—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK95106596T 1994-05-05 1995-05-02 Substituerede bicycliske heteroaroylguanidiner, fremgangsmåde til deres fremstilling, deres anvendelse som lægemiddel eller DK0682017T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4415873A DE4415873A1 (de) 1994-05-05 1994-05-05 Substituierte bizyklische Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Publications (1)

Publication Number Publication Date
DK0682017T3 true DK0682017T3 (da) 1999-12-13

Family

ID=6517371

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95106596T DK0682017T3 (da) 1994-05-05 1995-05-02 Substituerede bicycliske heteroaroylguanidiner, fremgangsmåde til deres fremstilling, deres anvendelse som lægemiddel eller

Country Status (19)

Country Link
US (1) US6093729A (fr)
EP (1) EP0682017B1 (fr)
JP (1) JP3774771B2 (fr)
KR (1) KR950032129A (fr)
CN (1) CN1117045A (fr)
AT (1) ATE183179T1 (fr)
AU (1) AU693861B2 (fr)
CA (1) CA2148666A1 (fr)
DE (2) DE4415873A1 (fr)
DK (1) DK0682017T3 (fr)
ES (1) ES2136767T3 (fr)
FI (1) FI952117L (fr)
GR (1) GR3031539T3 (fr)
HU (1) HUT72089A (fr)
IL (1) IL113606A0 (fr)
NO (1) NO304830B1 (fr)
NZ (1) NZ272058A (fr)
TW (1) TW429252B (fr)
ZA (1) ZA953588B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627193A (en) * 1995-02-09 1997-05-06 Mitsui Toatsu Chemicals, Inc. Quinoline-4-carbonylguanidine derivatives, process for producing the same and pharmaceutical preparations containing the compounds
DE19540995A1 (de) * 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19542306A1 (de) * 1995-11-14 1997-05-15 Hoechst Ag Sulfonylamino-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
PL316439A1 (en) * 1995-11-20 1997-05-26 Hoechst Ag Novel substituted derivatives of benzoyloguanidine, method of obtaining them, their application in production of pharmaceutic and diagnostic agents and pharmaceutic agent as such
DE19546736A1 (de) * 1995-12-14 1997-06-19 Hoechst Ag Substituierte Chromanylsulfonyl(thio)harnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Präparate
DE19548812A1 (de) * 1995-12-27 1997-07-03 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation
NZ314105A (en) * 1996-02-02 1997-12-19 Sumitomo Pharma Guanidine derivative substituted with a substituted indole which is peri condensed with a heterocyclic ring
DE19621483A1 (de) * 1996-05-29 1997-12-04 Hoechst Ag Substituierte 2-Naphthoylguanidine, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19621482A1 (de) * 1996-05-29 1997-12-04 Hoechst Ag Substituierte 1-Naphthoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US6258829B1 (en) 1997-03-06 2001-07-10 Toa Eiyo Ltd. Cycloalka[b]pyridine-3-carbonylguanidine derivatives, process for producing the same, and drugs containing the same
WO1998055475A1 (fr) * 1997-06-02 1998-12-10 Fujisawa Pharmaceutical Co., Ltd. Derives de guanidine utilises comme inhibiteurs de l'echange na+/h+ dans les cellules
AU4481899A (en) * 1998-02-20 1999-09-06 Takeda Chemical Industries Ltd. Aminoguanidine hydrazone derivatives, process for producing the same and drugs thereof
EP1182194A4 (fr) 1999-06-03 2004-02-11 Takeda Chemical Industries Ltd Preparations s'administrant par voie nasale
NZ544671A (en) * 2003-06-26 2009-02-28 Biotron Ltd Antiviral compounds and methods
CN104370813A (zh) * 2014-10-22 2015-02-25 上海大学 异喹啉-6-甲醛的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3780027A (en) * 1970-04-29 1973-12-18 Merck & Co Inc Anthranilic acid derivatives
DE3929582A1 (de) * 1989-09-06 1991-03-07 Hoechst Ag Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament
ES2089600T3 (es) * 1992-02-15 1996-10-01 Hoechst Ag Benzoilguanidina sustituida en 3,5, con efecto antiarritmico y efecto inhibidor de la proliferacion de celulas.
ATE158278T1 (de) * 1992-02-15 1997-10-15 Hoechst Ag Ortho-substituierte benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament oder diagnostikum sowie sie enthaltendes medikament
CZ284456B6 (cs) * 1992-02-15 1998-12-16 Hoechst Aktiengesellschaft Aminosubstituované benzoylguanidiny, způsob jejich přípravy, jejich použití jako léčiv a léčivo, které je obsahuje
EP0590455B1 (fr) * 1992-09-28 2000-12-27 Hoechst Aktiengesellschaft 1-(2H)-Isoquinoleines substituées à activité antiarrythmique et cardioprotective, procédé de préparation, médicaments les contenant et leur utilisation pour la préparation de médicaments pour traiter l'insuffisance cardiaque

Also Published As

Publication number Publication date
FI952117A7 (fi) 1995-11-06
FI952117L (fi) 1995-11-06
IL113606A0 (en) 1995-08-31
AU693861B2 (en) 1998-07-09
US6093729A (en) 2000-07-25
DE59506564D1 (de) 1999-09-16
NO304830B1 (no) 1999-02-22
ZA953588B (en) 1996-06-16
JPH0841028A (ja) 1996-02-13
CA2148666A1 (fr) 1995-11-06
TW429252B (en) 2001-04-11
EP0682017A1 (fr) 1995-11-15
EP0682017B1 (fr) 1999-08-11
AU1786195A (en) 1995-11-16
CN1117045A (zh) 1996-02-21
HUT72089A (en) 1996-03-28
NO951736L (no) 1995-11-06
JP3774771B2 (ja) 2006-05-17
ES2136767T3 (es) 1999-12-01
KR950032129A (ko) 1995-12-20
NO951736D0 (no) 1995-05-04
FI952117A0 (fi) 1995-05-03
NZ272058A (en) 1996-02-27
ATE183179T1 (de) 1999-08-15
DE4415873A1 (de) 1995-11-09
GR3031539T3 (en) 2000-01-31

Similar Documents

Publication Publication Date Title
DK0682017T3 (da) Substituerede bicycliske heteroaroylguanidiner, fremgangsmåde til deres fremstilling, deres anvendelse som lægemiddel eller
DK0699191T3 (da) Sulfonamider og derivater deraf, der modulerer aktiviteten af endotelin
ES2079534T3 (es) Derivados de polietilenglicol, sus peptidos modificados, metodos para producirlos y uso de los peptidos modificados.
FI925615A0 (fi) Stabiliserade farmaceutiska kompositioner, som innehaoller en hmg-coa-reduktas-inhibitorfoerening
EE03178B1 (et) Kondenseerunud bitsüklilist tuuma sisaldavad ühendid, nende vaheproduktid, valmistamismeetodid ja farmatseutilised kompositsioonid
DK160981C (da) Arylsulfonylurinstof-derivater, fremgangsmaade til fremstilling deraf, anvendelse af disse som terapeutisk og antineoplastisk middel samt farmaceutiske midler indeholdende saadanne derivater
FI920023A0 (fi) Heteroarylpiperazinfoereningar som antipsykotiska aemnen.
DK0973763T3 (da) Hidtil ukendte 2-(iminomethyl)aminophenylderivater, fremstilling af disse, anvendelse af disse i egenskab af lægemidler og farmaceutiske præparater indeholdende disse
DK160788D0 (da) 2-oen-phenyl(eller phenoxy)alkyl-n-methyl-aminoaaindan-forbindelser, anvendelse af sulfonamido-derivater blandt disse til fremstilling af antiarrhythmia-laegemidler og farmaceutiske praeparater indeholdende sulfonamiderne
DK0700380T3 (da) N-Alkylthiopolyaminderivater som radioprotektive midler
DK50086A (da) 3-phenyl-tetrahydropyridinderivater
DK431489D0 (da) Lipoprotein i (ompi) af pseudomonas aeruginosa, dets fremstilling og anvendelse
DK160688A (da) Ae5-alkylsulfonamido-2-(n-alkylsulfonamidoheterocyclylmethyl-n-methyl-amino)indan-forbindelser, deres anvendelse til fremstilling af antiarrhythmia-laegemidler og farmaceutiske praeparater indeholdende sulfonamiderne samt 2-(n-methylamino)indan-forbindelser, der er nyttige som mellemprodukterae
MX9102499A (es) Derivados de benzamida, procedimiento para su preparacion y composicion farmaceutica que los contiene.
PT861837E (pt) Novos compostos de 2-amino-indano processo para a sua preparacao e as composicoes farmaceuticas que os contem
YU82693A (sh) Farmaceutske formulacije disulfonil metana i novi disulfonil metani
SE8602525L (sv) Fenantrenderivat
ES271812Y (es) Parte de construccion para la ereccion de edificaciones o partes de las mismas.
DK437287D0 (da) 2,3-dihydrofuranderivater, deres fremstilling og deres anvendelse som mellemprodukter til fremstilling af tetrahydrofuranderivater
DK0521967T3 (da) Ny anvendelse af bambuterol
DK0553792T3 (da) Fremgangsmåde til fremstilling af dinatriumsalt,hemiheptahydratet af cefriaxon
DK0457215T3 (da) 3-deamino-4-desoxy-4-amino-8-fluoranthracycliner samt fremgangsmåder til fremstilling deraf
MX23335A (es) Derivados de acido glutarico y procedimiento para su preparacion.
FI934468A0 (fi) Bensenborsyraderivat, foerfarande foer deras framstaellning och deras anvaendning som sytesmellanprodukter
DK0516802T3 (da) Nye svovlholdige forbindelser, deres fremstilling og deres anvendelse som additiver til smøreolier